JP6993984B2 - 変異ボルデテラ菌株および使用方法 - Google Patents

変異ボルデテラ菌株および使用方法 Download PDF

Info

Publication number
JP6993984B2
JP6993984B2 JP2018551960A JP2018551960A JP6993984B2 JP 6993984 B2 JP6993984 B2 JP 6993984B2 JP 2018551960 A JP2018551960 A JP 2018551960A JP 2018551960 A JP2018551960 A JP 2018551960A JP 6993984 B2 JP6993984 B2 JP 6993984B2
Authority
JP
Japan
Prior art keywords
subject
pertactin
use according
mice
bordetella
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018551960A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513722A5 (enExample
JP2019513722A (ja
Inventor
ソラン，ルイ
ロヒト，カミーレ
ツィコプーロス，アン
ヤイア センディド，サリハ アイト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Institut National de la Santé et de la Recherche Médicale
Original Assignee
Institut Pasteur de Lille
Institut National de la Santé et de la Recherche Médicale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur de Lille, Institut National de la Santé et de la Recherche Médicale filed Critical Institut Pasteur de Lille
Publication of JP2019513722A publication Critical patent/JP2019513722A/ja
Publication of JP2019513722A5 publication Critical patent/JP2019513722A5/ja
Application granted granted Critical
Publication of JP6993984B2 publication Critical patent/JP6993984B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Developmental Biology & Embryology (AREA)
JP2018551960A 2016-03-29 2017-03-29 変異ボルデテラ菌株および使用方法 Active JP6993984B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662314843P 2016-03-29 2016-03-29
US62/314,843 2016-03-29
PCT/EP2017/057468 WO2017167834A1 (en) 2016-03-29 2017-03-29 Mutant bordetella strains and methods for use

Publications (3)

Publication Number Publication Date
JP2019513722A JP2019513722A (ja) 2019-05-30
JP2019513722A5 JP2019513722A5 (enExample) 2020-04-02
JP6993984B2 true JP6993984B2 (ja) 2022-02-03

Family

ID=58488973

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018551960A Active JP6993984B2 (ja) 2016-03-29 2017-03-29 変異ボルデテラ菌株および使用方法

Country Status (10)

Country Link
US (4) US10682377B2 (enExample)
EP (2) EP4541809A3 (enExample)
JP (1) JP6993984B2 (enExample)
CN (2) CN109069535B (enExample)
AU (2) AU2017242541B2 (enExample)
DK (1) DK3436034T3 (enExample)
ES (1) ES3027194T3 (enExample)
FI (1) FI3436034T3 (enExample)
SG (1) SG11201807783UA (enExample)
WO (1) WO2017167834A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007104451A1 (en) * 2006-03-10 2007-09-20 Institut Pasteur De Lille Live attenuated bordetella strains as a single dose vaccine against whooping cough
CN102448490B (zh) 2009-04-28 2015-05-13 国家健康与医学研究院 用于预防或治疗过敏原引起的气道疾病的疫苗
US10682377B2 (en) * 2016-03-29 2020-06-16 Institut Pasteur De Lille Mutant Bordetella strains and methods of use
EP3697439A1 (en) 2017-10-18 2020-08-26 Institut Pasteur de Lille Bordetella strains expressing serotype 3 fimbriae
AU2021325149A1 (en) 2020-08-14 2023-03-02 ILiAD Biotechnologies, Inc. Lyophilized live bordetella vaccines
CN116635517A (zh) * 2020-11-17 2023-08-22 伊利亚德生物技术有限公司 与神经退行性疾病相关的神经病理的治疗和预防
KR20250038747A (ko) 2022-07-22 2025-03-19 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 만성 폐쇄성 폐질환의 치료를 위한 보르데텔라 균주의 용도
WO2025257397A1 (en) 2024-06-14 2025-12-18 Institut National de la Santé et de la Recherche Médicale Live attenuated bordetella vaccines capable of producing and secreting heterologous antigens

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001507568A (ja) 1996-10-11 2001-06-12 アンスティテュ パストゥール ド リール ハイブリッドｆｈａを発現するボルデテラ株、リポソームおよびワクチン
JP2012525346A (ja) 2009-04-28 2012-10-22 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル アレルゲン駆動性気道病態の予防または治療のためのワクチン
WO2013066272A1 (en) 2011-11-02 2013-05-10 National University Of Singapore Effect of an attenuated bordetella strain against allergic disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713072B1 (en) 1987-11-02 2004-03-30 Chiron S.R.L. Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine
GB9115332D0 (en) * 1991-07-16 1991-08-28 Connaught Lab Manipulation of gene copy number in bordetella
FR2718750B1 (fr) 1994-04-19 1996-06-14 Pasteur Institut Protéines recombinantes de l'hémagglutinine filamenteuse de Bordetella, notamment, B. Pertussis, production et application à la production de protéines étrangères ou de principes actifs vaccinants.
DE69511392T2 (de) * 1994-04-28 2000-03-23 Takeda Chemical Industries, Ltd. Verfahren zur trennung von protektiven verbindungen aus bordetella pertussis
FR2840319B1 (fr) 2002-05-30 2004-08-20 Pasteur Institut Souches de bordetella rendues deficientes par attenuation genetique
US7582297B2 (en) 2003-04-11 2009-09-01 Medimmune, Llc Methods of treating respiratory conditions
WO2007104451A1 (en) 2006-03-10 2007-09-20 Institut Pasteur De Lille Live attenuated bordetella strains as a single dose vaccine against whooping cough
US20100111996A1 (en) 2006-11-15 2010-05-06 Denis Leclerc Papaya Mosaic Virus-Based Vaccines for Influenza
CA2678698A1 (en) 2007-02-23 2008-10-02 The Penn State Research Foundation Use of an avirulent bordetella mutant as a live vaccine vector
AU2008266910A1 (en) 2007-06-18 2008-12-24 Hemispherx Biopharma, Inc. Early intervention of viral infections with immune activators
CA2765364C (en) 2009-06-15 2015-05-26 National University Of Singapore Influenza vaccine, composition, and methods of use
CN102793915B (zh) * 2012-07-25 2013-10-23 天津康希诺生物技术有限公司 一种无细胞百日咳疫苗的生产方法
EP2722338A1 (en) 2012-10-17 2014-04-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel recombinant Bordetella strains
US10682377B2 (en) * 2016-03-29 2020-06-16 Institut Pasteur De Lille Mutant Bordetella strains and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001507568A (ja) 1996-10-11 2001-06-12 アンスティテュ パストゥール ド リール ハイブリッドｆｈａを発現するボルデテラ株、リポソームおよびワクチン
JP2012525346A (ja) 2009-04-28 2012-10-22 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル アレルゲン駆動性気道病態の予防または治療のためのワクチン
WO2013066272A1 (en) 2011-11-02 2013-05-10 National University Of Singapore Effect of an attenuated bordetella strain against allergic disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Euro Surveill，2014年，Vol.19, No.33，pii=20881
PLOS ONE, 2014，Vol.9, No.1，e83449

Also Published As

Publication number Publication date
ES3027194T3 (en) 2025-06-13
EP4541809A2 (en) 2025-04-23
US20200323901A1 (en) 2020-10-15
AU2022221438B2 (en) 2024-10-03
CN114767718A (zh) 2022-07-22
US10682377B2 (en) 2020-06-16
WO2017167834A1 (en) 2017-10-05
US20170283890A1 (en) 2017-10-05
CN109069535A (zh) 2018-12-21
SG11201807783UA (en) 2018-10-30
DK3436034T3 (da) 2025-05-12
JP2019513722A (ja) 2019-05-30
US11065276B2 (en) 2021-07-20
AU2017242541B2 (en) 2022-06-30
CA3018126A1 (en) 2017-10-05
FI3436034T3 (fi) 2025-05-08
EP4541809A3 (en) 2025-06-25
AU2022221438A1 (en) 2022-10-06
CN109069535B (zh) 2022-03-18
US20210290667A1 (en) 2021-09-23
US20230381224A1 (en) 2023-11-30
EP3436034A1 (en) 2019-02-06
AU2017242541A1 (en) 2018-10-11
EP3436034B1 (en) 2025-03-26

Similar Documents

Publication Publication Date Title
US20230381224A1 (en) Mutant Bordetella Strains and Methods of Use
Solans et al. The role of mucosal immunity in pertussis
JP2019513722A5 (enExample)
US12403188B2 (en) Bordetella strains expressing serotype 3 fimbriae
US20080254062A1 (en) Use of an avirulent bordetella mutant as a live vaccine vector
CN112449604A (zh) 用作有结核感染风险的患者的预防剂或用作治疗结核感染患者的辅助剂的组合物
CA3018126C (en) Mutant bordetella strains and methods of use
EP0535740B1 (en) Respiratory disease vaccine for cats
JP6867623B2 (ja) 百日咳モデル動物およびその作製方法、ならびに百日咳モデル動物を用いた方法
HK1262896B (en) Mutant bordetella strains and methods for use
HK1262896A1 (en) Mutant bordetella strains and methods for use
HK40115864A (en) Bordetella strains expressing serotype 3 fimbriae
HK40026630B (en) Bordetella strains expressing serotype 3 fimbriae
JP2023550052A (ja) 神経変性疾患に関連する神経病理の治療および予防
KR20250038747A (ko) 만성 폐쇄성 폐질환의 치료를 위한 보르데텔라 균주의 용도
Goel Interleukin-6 Contributes To Immunity Against Bordetella Pertussis.
HK40026630A (en) Bordetella strains expressing serotype 3 fimbriae

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210506

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210802

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211116

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211210

R150 Certificate of patent or registration of utility model

Ref document number: 6993984

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250